- H.C. Wainwright started reporting on Poseida Therapeutics Inc PSTX with a buy recommendation and a Price target of $15.
- Poseida is a clinical-stage biopharmaceutical company focused on the development of cell and gene therapies based on its proprietary platforms, including PiggyBac, Cas-CLOVER and nanoparticle technologies.
- The analyst writes that Poseida’s PiggyBac and Cas-CLOVER technologies could potentially address problems with current autologous CART therapies, such as: B. severe toxicities, limited efficacy in solid tumors and high manufacturing costs.
- HC Wainwright also writes that current mainstream in vivo gene therapy based on adeno-associated viruses (AAV) has several shortcomings. Therefore, the combination of PiggyBac and nanoparticles could potentially deliver virus-free, safe, and durable in vivo gene therapy, expanding indications and patient populations.
- Although Poseida’s in vivo gene therapy pipeline is still in the preclinical stage, the analyst says the promising data from the P-OTC-101 and P-FVIII-101 programs provide a proof of concept that in vivo gene therapy can be used Based on PiggyBac and nanoparticle platforms could achieve sustained efficacy, even in a juvenile patient population.
- The Company’s wholly owned P-OTC-101 program is expected to enter human trials in early 2024.
- Price promotion: PSTX shares are up 15.4% at $6.68 as of last check Wednesday.
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
[ad_2]
Source story
